MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e) On July 1, 2017, MabVax Therapeutics Holdings, Inc. (“Company”) entered into renewed employment agreements with each of J. David Hansen, its Chairman, President and Chief Executive Officer, Paul W. Maffuid, Ph.D., its Executive Vice President of Research and Development, and Gregory P. Hanson, CMA, MBA, its Chief Financial Officer (the “Employment Agreements”). The principal purpose of each of the Employment Agreements was to extend the term of each of Mr. Hansen’s, Dr. Maffuid’s and Mr. Hanson’s (the “Executives”) employment through July 1, 2020 as previously entered into employment agreements terminated or will terminate on July 1, 2017, July 21, 2017 and July 1, 2017, respectively. These agreements supersede and replace the Employment Agreements between the Company and each of Mr. Hansen and Mr. Hanson dated July 1, 2014 and the Employment Agreement between the Company and Dr. Maffuid dated July 21, 2014 (the “Prior Agreements”) and contain substantially the same terms as the Prior Agreements except as set forth below.

Employment Agreements

* Bonus is based on certain performance-based objectives established by the Company.

The Company’s entry of the Prior Agreements and summaries of the material terms thereof were disclosed in the Company’s Annual Report on Form 10-K filed on March 1, 2017, which summaries are qualified in their entirety by reference to the full text of the Prior Agreements, and filed as Exhibits 10.9 and 10.10 to the Company’s Quarterly Report on Form 10-Q filed on August 8, 2014 and Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q/A filed on August 12, 2015, which are incorporated herein by reference.

On July 1, 2017, the Company also entered into an amendment to its employment agreement with Wolfgang W. Scholz, Ph.D. to extend the term of Dr. Scholz’s employment under the employment agreement between the Company and Dr. Scholz dated July 1, 2014 to have a new expiration date of June 30, 2018. All other terms of Dr. Scholz’s employment agreement that were in effect prior to the amendment remain in effect. The entry of Dr. Scholz’s employment agreement and summaries of the material terms thereof were disclosed in the Company’s Current Report on Form 8-K filed on July 9, 2014, which summaries are qualified in their entirety by reference to the full text of the Dr. Scholz’s employment agreement, filed as Exhibit 10.11 to the Company’s Quarterly Report filed on Form 10-Q on August 8, 2014, which are incorporated herein by reference.